Psoriasis Clinical Trials in East Windsor, New Jersey

6 studies are recruiting for psoriasis in East Windsor, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

   The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06857942 on ClinicalTrials.gov

2. Taltz in Combination With Enstilar for Psoriasis

   Enstilar in combination with Taltz for plaque psoriasis.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey

   Run by

   Psoriasis Treatment Center of Central New Jersey

   See if you can join NCT04372277 on ClinicalTrials.gov

3. Duobrii in Combination With Biologics

   12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey

   Run by

   Psoriasis Treatment Center of Central New Jersey

   See if you can join NCT04119102 on ClinicalTrials.gov

4. ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

   Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey

   Run by

   Psoriasis Treatment Center of Central New Jersey

   See if you can join NCT04347473 on ClinicalTrials.gov

5. Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

   4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey

   Run by

   Psoriasis Treatment Center of Central New Jersey

   See if you can join NCT03827876 on ClinicalTrials.gov

6. An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

   A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Elise Nelson, East Windsor, New Jersey

   Run by

   Psoriasis Treatment Center of Central New Jersey

   See if you can join NCT03392337 on ClinicalTrials.gov